An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.
On the Monday Dec. 26 edition of Georgia Today: Where to recycle your Christmas tree, positive news for Alzheimer's patients, a look at the Savannah Bananas.
In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
Rather than treating patients in clinical trials with a specific drug, doctors are taking a more personalized approach by attempting to understand root causes of and the best treatments for diseases affecting cognitive decline, such as Alzheimer’s.
Mild cognitive impairment, a common brain condition, can be an early sign of Alzheimer's disease. But most people don't know the symptoms. And some may mistake it for normal aging.
Novelist Amy Bloom talks about how, at her husband's insistence, she traveled with him to Zurich so he could legally terminate his life. Her new memoir is In Love.
Arts therapies appear to ease brain disorders from Parkinson's to PTSD. Now, artists and scientists have launched an effort to understand how these treatments change the brain.
Microglia are amoeba-like cells that scour the brain for injuries and invaders. But sometimes the usually helpful cells go into overdrive and damage the brain, researchers say.
Scientists have created detailed maps of the brain area that controls movement in mice, monkeys and people. The maps could help explain human ailments like Alzheimer's and Lou Gehrig's disease.
By 2034, there will be 77 million people age 65 years and older compared to 76.5 million under the age of 18, according to the U.S. Census Bureau. There are roughly 7,300 geriatricians practicing in the United States and the American Geriatrics Society expects 30,000 geriatricians will be needed by 2030.
Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.
Researchers at Emory University's Brain Health Center hope to better understand the root causes of dementia diseases such as Alzheimer's and mental health disorders such as depression by examining individual patients' biological, medical and lifestyle factors.
Dr. Allan Levey is leading the Brain Health Personalized Medicine Institute at Emory University.
The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.
